Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-23T02:31:56.056Z Has data issue: false hasContentIssue false
  • English
  • Français

Rapid reversal of dilated cardiomyopathy following removal of neuroblastoma

Published online by Cambridge University Press:  19 August 2008

Luca Rosti ,
Pierluigi Festa  and
Carlo Corbetta
Luca Rosti*
Affiliation:
Department of Pediatrics and Neonatology, Istituti Clinici di Perfezionamento, Regina Elena Hospital, Milan, Italy Department of Cardiology / Cardiac Surgery, San Donato Hospital, San Donato Milanese, Milan, Italy
Pierluigi Festa
Affiliation:
Department of Cardiology / Cardiac Surgery, San Donato Hospital, San Donato Milanese, Milan, Italy
Carlo Corbetta
Affiliation:
Laboratorio, Istituti Clinici di Perfezionamento, Milan, Italy
*
Dr Luca Rosti, ICP-Ospedale Regina Elena, via Manfredo Fanti 6, 1–20122, Milan, Italy. Fax:39 0255185109
Get access Rights & Permissions [Opens in a new window]

Abstract

Reported is a child with dilated cardiomyopathy, in whom medical therapy resulted in a mild improvement of cardiac function. Metabolic studies suggested the presence of a catecholamine-secreting tumour; and an adrenal neuroblastoma was identified and surgically removed. Following surgery, there was progressive and complete normalization of cardiac function. Although very rare, neurogenic tumours may be involved in the development of a dilated cardiomyopathy in the infant and child.

Keywords

Dilated cardiomyopathyneuroblastomacatecholamine cardiomyopathychildren
Type
Brief Reports
Information
Cardiology in the Young , Volume 9 , Issue 5 , September 1999 , pp. 519 - 521
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Mestroni, L. Dilated cardiomyopathy: a genetic approach. Heart 1997; 77: 185–188.CrossRefGoogle ScholarPubMed
2.Sardesai, SH, Mourant, AJ, Sivathandon, Y, Farrow, R, Gibbons, DO. Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure. Br Heart J. 1990; 63: 234–237.Google Scholar
3.Imperato-McGinley, J, Gautier, T, Ehlers, K, Zullo, MA, Goldstein, DS, Vaughan, ED. Reversibility of catecholamine induced dilated cardiomyopathy in a child with pheochromocytoma. N Engl J Med 1987; 316: 793–797.Google Scholar
4.Joseph, T, Olivier, B, Magnier, S, Brugiβres, L, Casasoprana, A. Catecholamine cardiomyopathy in neuroblastoma. Arch Pediatr 1997; 4: 32–35.CrossRefGoogle ScholarPubMed
5.Maris, JM. Are certain children more likely to develop neuroblastoma? J Pediatr 1997; 131: 656–657.Google ScholarPubMed
6.Weinblat, ME, Heisel, MA, Siegel, SE. Hypertension in children with neurogenic tumors. Pediatrics 1983; 71: 947–951.CrossRefGoogle Scholar
7.Schaffer, MS, Zuberbuhler, P, Wilson, G, Rose, V, Duncan, WJ, Rowe, RD. Catecholamine cardiomyopathy: an unusual presentation of pheochromocytoma in children. J Pediatr 1981; 99: 276–279.CrossRefGoogle ScholarPubMed
8.Gersony, WM. The child with dilated cardiomyopathy: prognostic considerations and management decisions. J Am Coll Cardiol 1991; 18: 157–158.Google Scholar
9.Limas, CJ. Cardiac autoantibodies in dilated cardiomyopathy. A pathogenetic role? Circulation 1997; 95: 1979–1980.CrossRefGoogle ScholarPubMed
10.Chen, L, Re, RN, Prakash, O, Mondal, D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. PSEBM 1991; 196: 280–283.Google Scholar